Vascular Endothelial Growth Factor (VEGF) Pathway
- 1 October 2006
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 1 (8) , 768-770
- https://doi.org/10.1097/01243894-200610000-00003
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- VEGF Receptor Signal TransductionScience's STKE, 2001
- Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and AngiogenesisCell, 1999
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.Proceedings of the National Academy of Sciences, 1995
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971